Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma

@inproceedings{Rao2016PreclinicalJO,
  title={Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma},
  author={Donald D. Rao and Christopher M Jay and Zhaohui Wang and Xiuquan Luo and Padmasini Kumar and Hilary Eysenbach and Maurizio L. Ghisoli and Neil N. Senzer and John Nemunaitis},
  booktitle={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2016}
}
The EWS/FLI1 fusion gene is well characterized as a driver of Ewing's sarcoma. Bi-shRNA EWS/FLI1 is a functional plasmid DNA construct that transcribes both siRNA and miRNA-like effectors each of which targets the identical type 1 translocation junction region of the EWS/FLI1 transcribed mRNA sequence. Previous preclinical and clinical studies confirm the safety of this RNA interference platform technology and consistently demonstrate designated mRNA and protein target knockdown at greater than… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
4 Citations
75 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 75 references

Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell” immunotherapy (FANGTM) in advanced cancer

  • N Senzer, J Nemunaitis, M Barve, D Orr, J Kuhn, M Magee
  • J Vaccines and Vaccination
  • 2013

Similar Papers

Loading similar papers…